Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Long-term results of the UNICANCER ACCORD 16 phase II trial

Antonin Levy; David Azria; Jean Pierre Pignon; Anne Delarochefordiere; Isabelle Martel-Lafay; Emmanuel Rio; David Malka; Thierry Conroy; Laurent Miglianico; Yves Becouarn; Katty Malekzadeh; Julie Leclercq; Beata Juzyna; Patrick Ezra; Claire Lemanski; Eric Deutsch

doi:10.1016/j.radonc.2015.02.008

Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Long-term results of the UNICANCER ACCORD 16 phase II trial

Antonin Levy, David Azria, Jean Pierre Pignon, Anne Delarochefordiere, Isabelle Martel-Lafay, Emmanuel Rio, David Malka, Thierry Conroy, Laurent Miglianico, Yves Becouarn, Katty Malekzadeh, Julie Leclercq, Beata Juzyna, Patrick Ezra, Claire Lemanski, Eric Deutsch

Research output: Contribution to journal › Letter › peer-review

31 Scopus citations

Original language	English
Pages (from-to)	415-416
Number of pages	2
Journal	Radiotherapy and Oncology
Volume	114
Issue number	3
DOIs	https://doi.org/10.1016/j.radonc.2015.02.008
State	Published - 1 Mar 2015
Externally published	Yes

Bibliographical note

Funding Information:
This study was funded by a medical Grant from Merck KGaA . Merck KGaA have reviewed this manuscript but the views and opinions described do not necessarily reflect those of Merck KGaA.

Funding

This study was funded by a medical Grant from Merck KGaA . Merck KGaA have reviewed this manuscript but the views and opinions described do not necessarily reflect those of Merck KGaA.

Funders	Funder number
Merck KGaA

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.radonc.2015.02.008

Cite this

Levy, A., Azria, D., Pignon, J. P., Delarochefordiere, A., Martel-Lafay, I., Rio, E., Malka, D., Conroy, T., Miglianico, L., Becouarn, Y., Malekzadeh, K., Leclercq, J., Juzyna, B., Ezra, P., Lemanski, C., & Deutsch, E. (2015). Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Long-term results of the UNICANCER ACCORD 16 phase II trial. Radiotherapy and Oncology, 114(3), 415-416. https://doi.org/10.1016/j.radonc.2015.02.008

@article{e60c850d2d90472ab2193429861b34dc,

title = "Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Long-term results of the UNICANCER ACCORD 16 phase II trial",

author = "Antonin Levy and David Azria and Pignon, {Jean Pierre} and Anne Delarochefordiere and Isabelle Martel-Lafay and Emmanuel Rio and David Malka and Thierry Conroy and Laurent Miglianico and Yves Becouarn and Katty Malekzadeh and Julie Leclercq and Beata Juzyna and Patrick Ezra and Claire Lemanski and Eric Deutsch",

note = "Funding Information: This study was funded by a medical Grant from Merck KGaA . Merck KGaA have reviewed this manuscript but the views and opinions described do not necessarily reflect those of Merck KGaA.",

year = "2015",

month = mar,

day = "1",

doi = "10.1016/j.radonc.2015.02.008",

language = "אנגלית",

volume = "114",

pages = "415--416",

journal = "Radiotherapy and Oncology",

issn = "0167-8140",

publisher = "Elsevier Ireland Ltd",

number = "3",

}

Levy, A, Azria, D, Pignon, JP, Delarochefordiere, A, Martel-Lafay, I, Rio, E, Malka, D, Conroy, T, Miglianico, L, Becouarn, Y, Malekzadeh, K, Leclercq, J, Juzyna, B, Ezra, P, Lemanski, C & Deutsch, E 2015, 'Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Long-term results of the UNICANCER ACCORD 16 phase II trial', Radiotherapy and Oncology, vol. 114, no. 3, pp. 415-416. https://doi.org/10.1016/j.radonc.2015.02.008

Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Long-term results of the UNICANCER ACCORD 16 phase II trial. / Levy, Antonin; Azria, David; Pignon, Jean Pierre et al.
In: Radiotherapy and Oncology, Vol. 114, No. 3, 01.03.2015, p. 415-416.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer

T2 - Long-term results of the UNICANCER ACCORD 16 phase II trial

AU - Levy, Antonin

AU - Azria, David

AU - Pignon, Jean Pierre

AU - Delarochefordiere, Anne

AU - Martel-Lafay, Isabelle

AU - Rio, Emmanuel

AU - Malka, David

AU - Conroy, Thierry

AU - Miglianico, Laurent

AU - Becouarn, Yves

AU - Malekzadeh, Katty

AU - Leclercq, Julie

AU - Juzyna, Beata

AU - Ezra, Patrick

AU - Lemanski, Claire

AU - Deutsch, Eric

N1 - Funding Information: This study was funded by a medical Grant from Merck KGaA . Merck KGaA have reviewed this manuscript but the views and opinions described do not necessarily reflect those of Merck KGaA.

PY - 2015/3/1

Y1 - 2015/3/1

UR - http://www.scopus.com/inward/record.url?scp=84927571118&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2015.02.008

DO - 10.1016/j.radonc.2015.02.008

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 25769380

AN - SCOPUS:84927571118

SN - 0167-8140

VL - 114

SP - 415

EP - 416

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

IS - 3

ER -

Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Long-term results of the UNICANCER ACCORD 16 phase II trial

Bibliographical note

Funding

UN SDGs

Access to Document

Other files and links

Cite this